CHOICELY
The Eurovision Song Contest (ESC), the world’s largest live music event, has renewed their mobile app in time for this year’s event in Malmö, Sweden. The app was built using Choicely’s no code app platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501446902/en/
Eurovision Song Contest built their new mobile app with a no code platform. The app was built using Choicely’s no code app platform. The Eurovision app boasts an extensive news feed and media portal, and engagement tools full of interactive fan activations like the Scoreboard. With it, viewers can establish their own classic Eurovision ranking from 12 points on, and share the ranking on social media. (Graphic: Business Wire)
“We were looking for a specialized partner who enables us to develop our app with speed and flexibility, so we can better serve the Eurovision fans across the globe,“ says Dave Goodman, ESC Digital and Communications Manager for Contest organizers, the European Broadcasting Union.
“We definitely got all of that in Choicely, and more,” Goodman emphasizes.
With Choicely, the app can be built without coding, using a visual drag and drop interface instead – like Wix or Wordpress for mobile apps.
“Despite Choicely being a no code platform, we got a fully tailormade app that matches our needs and our brand. Making improvements is quick and easy. We can focus on engaging our fans!” adds Dave Goodman from the EBU.
The Eurovision app boasts an extensive news feed and media portal, and engagement tools full of interactive fan activations like the Scoreboard. With it, viewers can establish their own classic Eurovision ranking from 12 points on, and share the ranking on social media.
During the Semi-Finals and Grand Final, viewers around the world can also easily vote through the app.
“We are proud to co-operate with the Eurovision Song Contest!” says Kaius Meskanen, CEO of Choicely. “It’s a legendary contest with a passionate global fanbase, and it reflects in everything they do,” Meskanen says.
“Together we have created a pixel-perfect app to serve the Eurovision fans, during the shows and in between them. It’s great to see the ESC organization enjoying the benefits of no code, like lower development costs, agile updates, and a better overall experience for the fans,” Meskanen points out.
Choicely was founded in Finland and it’s used by leaders in media, sports and entertainment companies, and across a range of industries in over 50 countries.
The renewed Eurovision Song Contest app can be found in Apple App Store and Google Play Store.
The Eurovision Song Contest is the world’s largest live music event. It is organized annually by the European Broadcasting Union (EBU), the world’s foremost alliance of public service media (PSM).
The competition, in which participating public service broadcasters that are Members of the EBU, send a new song to represent their nation, has taken place every year since 1956 except in 2020.
27 broadcasters have won the competition at least once.
37 broadcasters will take part in the 2024 Eurovision Song Contest in Malmö, Sweden hosted by SVT.
The 2023 competition reached over 170 million viewers around the world on TV and online.
The EBU represents 112 media organisations in 56 countries in Europe, the Middle East, and Africa; and have an additional 31 Associates in Asia, Africa, Australia, and the Americas. The EBU strives to secure a sustainable future for public service media.
Choicely’s no code app builder offers a simple, fast and affordable way to build and maintain high quality mobile apps. Choicely is based in Finland and Switzerland and currently serves businesses in over 50 countries. Choicely’s customers include the Eurovision Song Contest, Miss Universe, ITV Studios / Love Island TV Shows, and Iceland's national broadcasting organization RÚV.
Learn more about Choicely on their website.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501446902/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom